Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis. The company's product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-97.17M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -1197.81% |
| Return on Assets (Trailing 12 Months) | -264.95% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.75 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.75 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.06 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.12 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.70 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 130.46M |
| Free Float | 124.46M |
| Market Capitalization | $152.64M |
| Average Volume (Last 20 Days) | 6.32M |
| Beta (Past 60 Months) | 1.46 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 51.82% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |